L.
Allott‡
,
C.
Da Pieve‡
,
D. R.
Turton
and
G.
Smith
*
Division of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK. E-mail: graham.smith@icr.ac.uk; Fax: +44 (0)2073705261; Tel: +44 (0)2087224482
First published on 16th January 2017
The aluminium fluoride-18 ([18F]AlF) radiolabelling procedure has generated great interest because it is a simple, one-pot method that can be used to directly radiolabel small molecules, peptides and proteins without the requirement for a [18F]fluoride drying step. Reported here is the development of an automated [18F]AlF radiolabelling procedure of three different precursors (one small molecule and two peptides) on two automated synthesis platforms: GE TRACERlab FXFN and Trasis AllInOne (AIO). Aiming at the clinical translatability of a [18F]AlF radiosynthetic methodology, the use of both platforms yielded radioconjugates with >98% radiochemical purity (RCP) within 26–35 min and required a single rapid purification step. The Trasis AIO platform gave improved [18F]fluoride incorporation, and generally produced radioconjugates with a higher radiochemical yield (RCY) and effective specific activities (SA) when compared to the GE TRACERlab FXFN system.
McBride et al. described the preparation of a lyophilised kit which provided a potential starting point for the standardised production of [18F]AlF-based radiopharmaceuticals.7 Additionally, Yu et al. reported the feasibility of [18F]AlF radiolabelled NOTA-PRGD2 “[18F]Alfatide” in healthy volunteers and in patients with brain metastases.13 This demonstrates an increased interest in applying the [18F]AlF radiolabelling technique for the preparation of radiopharmaceuticals for clinical application.
This study describes the development of a general [18F]AlF automated radiolabelling procedure. Two different platforms, a GE TRACERlab FXFN and a Trasis AllInOne (AIO), were trialled and three azamacrocycle-containing substrates were radiolabelled (Fig. 1). NOTA-octreotide and NOTA-RGDfK were selected because they are commercially available and have been previously extensively radiolabelled using the [18F]AlF method.14–16 The tetrazine functionalised NODA macrocycle (NODA-Tz) was used as a representative of small molecules. Compounds having a similar structure to NODA-Tz have been radiolabelled with the [18F]AlF complex and employed for the bioorthogonal pre-clinical imaging of tumour xenografts in mice.8 The two automated platforms used in the study are widely used for the production of radiopharmaceuticals under GMP conditions.
![]() | ||
Fig. 1 The three different azamacrocycle-containing substrates used in the study: NODA-Tz (A), NOTA-octreotide (B), NOTA-RGDfK (C) and the general radiolabelling reaction (insert). |
The GE TRACERlab FXFN is built around a fixed reactor vessel with components which are attached to fixed locations. Reagents are manipulated from glass reservoirs to the reactor by gas pressure. The Trasis AIO platform is a cassette based system that mimics hands on processes (e.g. with the use of replaceable syringes and plastic manifolds) by using syringe drives and tap turners; as the cassette is a disposable component, the synthesis is more GMP compatible than a fixed reactor system. Additionally, the platforms are managed by two different types of automation software. In the GE TRACERlab FXFN system, the process is controlled by a time list with only limited feedback from the platform. The Trasis AIO process is controlled by a combination of timed steps and feedback from the platform regarding that the correct syringe position, temperature or pressure has been achieved.
In this study, the radiolabelling was initially investigated on the GE TRACERlab FXFN system to find indicative trends in radiolabelling performance by changing reaction conditions (e.g. volumes, buffer and substrate quantities) which were subsequently applied to the Trasis AIO platform.
The NODA-Tz small molecule (4) has been designed and synthesised in our lab (Scheme 1). Having previously shown a high [18F]AlF radiolabelling efficiency, the NODA macrocycle was chosen in preference to the more commonly used NOTA chelator.5,17 In brief, product 4 was prepared by attaching a 6-carbon alkyl linker to 4-cyanophenol to access compound 1 which was converted into tetrazine 2 in one step following a simple literature procedure.18 Tetrazine 3, derived from the tosylation of 2, was reacted with NO2AtBu and subsequently deprotected using TFA. The desired product 4 was obtained in a high purity after RP-HPLC purification. All purified compounds were characterised by 1H and 13C-NMR and ESI-HRMS (ESI†).
If larger volumes of [18F]fluoride are to be used, a concentration step using an anion exchange cartridge could be employed and placed before the reactor on the GE TRACERlab FXFN (Fig. 2) and eluted following the procedure described by Meyer et al.8 Alternatively, the production of a high radioactive concentration of [18F]fluoride for clinical applications will remove the necessity of a [18F]fluoride concentration procedure; instead, a concentrated [18F]fluoride aliquot (300–380 μL) can be used directly with this method.
The effect of the conjugate amount on the incorporation, radiochemical yield (RCY, isolated and decay corrected to the start of reaction) and effective specific activity (SA) of the final radioconjugates was subsequently investigated. For this purpose three quantities of substrate (30, 40, and 60 nmol) were radiolabelled using the same amount of [18F]fluoride activity (ca. 1000 MBq). The incorporation of [18F]fluoride was determined from the RP-HPLC chromatogram of the crude reaction mixture, however unreacted [18F]fluoride can be retained on the HPLC column which could lead to over-estimation of the incorporation.19
As shown in Fig. 3 and Table S1,† an increase of the quantities of each of the studied compounds corresponds to an improvement of the [18F]fluoride incorporation, RCY and the SA of the final product. Mostly, the incorporation and radiochemical yields appear to increase with increased amount of conjugate. Effective specific activities of the final products are less affected by the initial substrate quantity. However, full optimisation of the [18F]AlF radiolabelling was beyond the scope of this work and would be largely dependent on the local requirements of the application for the radioconjugate.
A single final purification step using HLB-SPE was sufficient to access the final radioconjugates with a RCP >98% (Fig. S2B, S3B, and S4B†). To ensure that the SPE cartridge was efficiently trapping the products and therefore providing the best RCY possible, a test using two cartridges placed in series was carried out. The presence of a negligible amount of radioactivity trapped on the second cartridge confirmed that the products were efficiently loaded by the automated system and were effectively trapped onto the HLB-SPE cartridge. The radioconjugates were eluted with 50% EtOH/H2O (300–500 μL) and were suitable for use in pre-clinical applications after dilution with either PBS or 0.9% sodium chloride solution. The total production time was 35 min. A schematic representation of the GE TRACERlab FXFN system is shown in Fig. 2 together with a list of the radiolabelling reaction steps. A more detailed description of the automated radiolabelling process can be found in the ESI† (Materials and methods, Section 3).
A schematic representation of the Trasis AIO system is shown in Fig. 5 together with a list of the radiolabelling reaction steps. A more detailed description of the automated radiolabelling process can be found in the ESI† (Materials and methods, Section 4).
The production time was 26 min. [18F]AlF-NODA-Tz and [18F]AlF-NOTA-octreotide showed a >60% [18F]fluoride incorporation, a >45% RCY, and a >10 MBq nmol−1 SA (Table 1). As seen in Fig. 4, the [18F]fluoride incorporation, the RCY and SA of the radioconjugates were generally higher when the Trasis AIO platform was used compared to the GE TRACERlab FXFN system. The effective control over the movement of reagents and reaction mixtures around the Trasis AIO cartridge based system may be responsible for that. However, the overall production efficiency of the [18F]AlF-NOTA-RGDfK radioconjugate showed minimal variation between the two platforms. This suggests that the radiolabelling procedure and purification were dependent not only on the reaction conditions but also on the physical and structural properties of the molecules of interest (e.g. amino acid sequence, chain length) which could influence the interaction with the surfaces of the reaction vessels and tubing of the automation platform.
Substrate | Quantity (nmol) | Incorporation (%) | RCY (%) | SA (MBq nmol−1) |
---|---|---|---|---|
NODA-Tz | 60 | 68.1 ± 6.1 | 48.2 ± 1.4 | 11.4 ± 2.0 |
NOTA-RGDfK | 60 | 48.3 ± 10.6 | 15.3 ± 6.5 | 7.4 ± 1.1 |
NOTA-octreotide | 60 | 75.0 ± 1.8 | 56.2 ± 4.2 | 12.7 ± 0.14 |
![]() | ||
Fig. 5 Schematic representation of the [18F]AlF radiochemistry set up (A) and overview of the automated radiolabelling processes (B) for the Trasis AIO system. |
The general radiolabelling method described here can be used as a starting point for further optimisation to progress a substrate of interest into a clinical setting.
This study aimed to develop a general method suitable for the automation of [18F]AlF radiochemistry which was applied to the GE TRACERlab FXFN and Trasis AIO platforms. The radiolabelling conditions were studied using a selection of azamacrocycle-containing molecules including two commercially available peptides and one in-house synthesised small molecule. Initially, the [18F]AlF radiochemistry was developed using the GE TRACERlab FXFN system and subsequently transferred to the Trasis AIO platform. Purification of the products by HLB-SPE was sufficient to provide radioconjugates with high radiochemical purity (>98%) and the total reaction times were 26–35 min. Currently, the method described is suitable for accessing radioconjugates for pre-clinical studies. Further work would be required to maximise radiochemical yield for a chosen substrate and to optimise the purity profile of the final product prior to patient use. This process should ensure that regulatory parameters are met. The production of large radioactivity batches of GMP grade radiopharmaceuticals for multi-patient doses allows off-site transportation to “satellite” PET centres and facilitates commercial accessibility to these imaging agents. Although the final products were successfully prepared using both automated systems, the cassette based Trasis AIO enabled the highest [18F]fluoride incorporation and gave products with the highest RCY and SA compared to the GE TRACERlab FXFN, most likely due to a greater control over reagent handling. Both the GE TRACERlab FXFN and Trasis AIO systems can be used for the [18F]AlF radiolabelling of peptides and small molecules and have great potential for the cGMP productions of [18F]AlF radiopharmaceuticals for routine clinical use.
NOTA | 1,4,7-Triazacyclononane-1,4,7-triacetate |
NODA | 1,4,7-Triazacyclononane-1,4-diacetate |
TCO | trans-Cyclooctene |
IEDDA | Inverse-electron demand Diels–Alder |
NO2AtBu | 2,2′-(1,4,7-Triazacyclononane-1,4-diyl)diacetate |
DIPEA | N,N-Diisopropylethylamine |
TFA | Trifluoroacetic acid |
RCP | Radiochemical purity |
SPE | Solid phase extraction |
Rt | Retention time |
NaOAc | Sodium acetate |
DMSO | Dimethyl sulfoxide |
DCM | Dichloromethane |
EtOAc | Ethyl acetate |
EtOH | Ethanol |
DMF | Dimethylformamide |
SA | Effective specific activity |
SD | Standard deviation |
RCY | Radiochemical yield |
MeCN | Acetonitrile |
TEA | Triethylamine |
GMP | Good manufacturing process |
cGMP | Current good manufacturing process |
Footnotes |
† Electronic supplementary information (ESI) available: Materials and methods, analytical data for tetrazine (1H/13C NMR and MS), RP-HPLC chromatograms and GE Tracer Lab FX FN radiolabelling efficiency table. See DOI: 10.1039/c6re00204h |
‡ Equal contribution for first authorship. |
This journal is © The Royal Society of Chemistry 2017 |